The Cytokine Language of Still's Disease and MAS

Moderator(s)

• 

  Lauren Henderson, MD, MSc

  Boston Children's Hospital
  Watertown, Massachusetts, United States

  Disclosure(s): Bristol-Myers Squibb(BMS): Grant/Research Support (Ongoing); Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 12, 2024); Sobi: Consultant (Ongoing)
• SC

  Susan Canny, MD, PhD

  Seattle Children's Hospital/University of Washington
  Seattle, WA, United States

  Disclosure(s): Sobi: Consultant (Ongoing)

Session Coordinator(s)

• PL

  Pui Lee, MD, PhD

  Boston Children's Hospital
  Newton, Massachusetts, United States

  Disclosure(s): Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, January 31, 2025)

Still’s disease (also called systemic juvenile idiopathic arthritis) is the most severe form of JIA. Some patients with Still’s disease are prone to develop a life-threatening cytokine storm called macrophage activation syndrome (MAS). Early detection of Still’s disease and MAS is essential to minimize mortality and morbidity. This session will review recent developments in defining biomarkers for the diagnostic evaluation and management of Still’s disease and associated MAS.

Presentations:

• 2:30 PM – 3:00 PM Central Time

  IL-18 as a Guide to the Evaluation and Management of Still's Disease
  

  Speaker: Scott Canna, MD – Children's Hospital of Philadelphia
• 3:00 PM – 3:30 PM Central Time

  Biomarkers of Still's Disease and Macrophage Activation Syndrome
  

  Speaker: Alexei Grom, MD (he/him/his) – Cincinnati Children's Hospital Medical Center